Article
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Mar 2006
Wardelmann Eva, Merkelbach-Bruse Sabine, Pauls Katharina, Thomas Nadja, Schildhaus Hans-Ulrich, Heinicke Thomas, Speidel Nicola, Pietsch Torsten, Buettner Reinhard, Pink Daniel, Reichardt Peter, Hohenberger Peter
Abstract excerpt
Gastrointestinal stromal tumors (GIST) are characterized by a strong KIT receptor activation most often resulting from KIT mutations. In a smaller subgroup of tumors without KIT mutations, analogous activating mutations are found in the platelet-derived growth factor receptor alpha (PDGFRalpha) gene. Both PDGFRalpha and KIT receptors are targets of the tyrosine kinase inhibitor imatinib (Glivec) which has...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.